Healthcare · Pharmaceuticals & Biotechnology
Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. The company manufactures and markets more than 350 finished-dosage formulations and around 80 active pharmaceutical ingredients (APIs), covering therapeutic areas that include pain management, rheumatology, antimalarials, cardiovascular medicine, dermatology and anti-diabetics, and has an emerging biosimilars business. Its products are sold in over 100 countries, and it is one of India's larger API exporters, supplying more than 70 countries.
Source: Wikipedia
| Fiscal year | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Total income (before exceptional items) | 7,431† | — | 6,278† | 5,929† | 5,455† |
| Net profit | 1,133 | 651 | 530 | 506 | 871† |
₹ Crore. † Summed from the four quarterly filings of that fiscal year.
Current board roster from exchange filings. Director remuneration is not in our data, so it isn't shown.
| Name | Designation | Term end |
|---|---|---|
| A. K. Jain | Executive Director | June 30, 2026 |
| Pranay Godha | Executive Director | June 30, 2026 |
| Prashant Godha | Executive Director | June 30, 2026 |
| Premchand Godha | Executive Director | June 30, 2026 |
| Kamal Kishore Seth | Independent Director | June 30, 2026 |
| Narendra Mairpady | Independent Director | June 30, 2026 |
| Swati Patankar | Independent Director | June 30, 2026 |
| Vivek Keshav Shiralkar | Independent Director | June 30, 2026 |
Key management names, their remuneration, subsidiaries and brand listings are not in the exchange filings we ingest yet, so they are not shown here rather than estimated.
